FDA panel endorses first-of-a-kind cancer blood test from Grail designed to spot signs of various cancers in apparently healthy people

WASHINGTON (AP) — Federal health advisers on Wednesday endorsed a blood test designed to spot signs of various cancers in apparently healthy people while warning that it’s far from clear how well the technology works. Grail Inc.’s Galleri test doesn’t diagnose cancer but instead, with a single blood draw, looks for a signal that someone may have one of a long list of tumors. Those who receive a positive result need additional care to tell if they’re really sick. The Food and Drug Administration’s advisory panel voted 7-2, with one abstention, that the DNA-based test offers more potential benefits than...